Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 24, 2008

Clinical Data and Affymetrix Sign  Marketing Deal for New Drug Metabolism Service

  • Clinical Data and Affymetrix signed a marketing agreement for Affymetrix’ drug metabolizing enzymes and transporter (DMET) early access solution. Cogenics and Epidauros Biotechnologie, both subsidiaries of Clinical Data, will offer the DMET services on a global basis, with limited exclusivity in Europe.

    The DMET early access solution provides a method for assaying the genetics of drug metabolism, according to Affymetrix.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »